Assessing Fluid-responsiveness Using Non-invasive Hybrid Diffuse Optics on Peripheral Muscle (hDOS-CO)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jaume Mesquida Senior Clinical Researcher, MD
- Phone Number: +34 616722287
- Email: jmesquida@tauli.cat
Study Locations
-
-
Spain/ Barcelona
-
Sabadell, Spain/ Barcelona, Spain, 08208
- Recruiting
- Parc Taulí Hospital Universitari
-
Contact:
- Jaume Mesquida Senior Clinical Researcher, MD
- Phone Number: +34 616722287
- Email: jmesquida@tauli.cat
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Invasive blood pressure monitoring through an arterial line
Exclusion Criteria:
- Patients with suspected pregnancy
- Intra-abdominal hypertension
- Elevated intracranial pressure
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Critical care patient
Critical care patients with their blood pressure invasively monitored through an arterial line
|
The PLR will be performed using automatic bed adjustment: Starting from a semi-recumbent position, the lower limbs will be elevated to a 45° angle while the trunk will be moved from semi-recumbent to supine.
After three minutes, subjects will be returned to the initial semi-recumbent position.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cardiac Output Response
Time Frame: During procedure
|
The relative increase in % of the Cardiac Output (CO), from baseline during the Passive Leg Raising (PLR) test (at 60-120 seconds within the maneuver), will be calculated.
Those subjects with a relative increase equal to or above 10% will be classified as CO-responders to the PLR.
On the other hand, if the increase in CO during the PLR is below 10%, subjects will be classified as non-responders.
|
During procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CEIm 2024/3001
- INN2024003 (Other Grant/Funding Number: Institut d'Investigació i Innovació Parc Taulí)
- CIR2023014 (Other Grant/Funding Number: Institut d'Investigació i Innovació Parc Taulí)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.